Trial Profile
The effect of metformin versus placebo, including three insulin-analogue regimens with variating postprandial glucose regulation, on CIMT in T2DM patients - A randomized, multicenter trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart (Primary) ; Insulin detemir (Primary) ; Metformin (Primary)
- Indications Diabetic angiopathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CIMT
- 01 Jan 2022 Results of a post hoc analysis assessing the effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes published in the Free Radical Biology and Medicine
- 01 Sep 2021 Results of exploratory sub-study of the Copenhagen Insulin and Metformin Therapy trial (n=407) assessing long-term effects of metformin compared with placebo on whole body bone and body composition measures in patients with type 2 diabetes mellitus, published in the Osteoporosis International.
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes